It is generally acknowledged that using DNMT inhibitors in cancer therapy can rejuvenate immune responses in the TME, partly by re-activating silenced immune genes in both tumor cells and infiltrating macrophages [104,191,192,193]. The gene discussed is DNMT1; the disease is cancer.